Prepare for up to a Dozen Humira Biosimilars

November 2022

Up to 12 biosimilars for Humira (adalimumab) are slated to hit the market in 2023...starting with Amjevita in January.

This is a big deal. Humira is approved for several indications...rheumatoid arthritis, plaque psoriasis, Crohn’s, etc.

Plus it’s a top seller...annual revenue is over $20 billion.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote